Corporate Member Update: Regeneron-REGEN-COV™ (casirivimab and imdevimab)

On September 9th, 2021, the U.S. Food and Drug Administration (FDA) updated Regeneron’s Emergency Use Authorization (EUA) to authorize an additional presentation of REGEN-COV™ (casirivimab and imdevimab) – specifically a co-packaged presentation of REGEN-COV that consists of individual vials of both casirivimab and imdevimab inside a single carton.

To read the full press release, click here.